A research perspective published on March 11 in Volume 13 of Oncoscience reports that the COCOON trial's prophylactic regimen has significantly reduced skin toxicities for patients with EGFR-mutant non-small cell lung cancer receiving first-line amivantamab plus lazertinib.
The findings are important because dermatologic side effects often limit the use of targeted therapies, potentially leading to dose reductions or discontinuation. Reducing these adverse events could help patients better tolerate and benefit from their prescribed treatments.
Led by Bishal Tiwari from Nassau University Medical Center and Asmita Koirala from Western Regional Hospital in Nepal, the commentary outlines a structured protocol involving oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. The interim analysis found that moderate-to-severe dermatologic adverse events dropped from 76.5% with standard reactive care to 38.6% with the COCOON regimen. There were also fewer severe (grade ≥3) events and fewer treatment discontinuations observed among those receiving proactive supportive care.
"The COCOON results emphasize the clinical value of anticipating EGFR inhibitor-related toxicities through multidisciplinary supportive care," said the authors.
According to Tiwari and Koirala, these early results support integrating dermatologic prevention into first-line treatment plans for EGFR-mutant non-small cell lung cancer. They highlight that simple and low-cost interventions can improve patient tolerability while maintaining dose intensity. The authors suggest that future updates to clinical practice may include more widespread adoption of proactive supportive care approaches.
